In the IMpower010 trial, adjuvant atezolizumab significantly prolonged DFS, particularly in patients with PD-L1 expression ≥ 1% (HR = 0.66), leading to its approval for adjuvant treatment in PD-L1 ≥ 1% stage II-IIIA NSCLC [40]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.